Deutsche Bank AG Acquires Shares of 376,245 Neogen Corporation $NEOG

Key Points

• Deutsche Bank initiated a stake in Neogen. It purchased 376,245 shares worth approximately $3.38 million, while institutional investors collectively held 96.73% of the company.
• Neogen exceeded quarterly expectations. The company reported $0.09 in adjusted earnings per share versus a $0.06 consensus estimate and revenue of $225.3 million, above expectations, though revenue edged down year over year and net margin remained negative.
• Analyst sentiment improved but remains mixed. Piper Sandler upgraded Neogen to “overweight” and raised its price target to $14, while the broader analyst consensus remains “Hold” with a $12 target; earnings forecasts were generally raised but included a reduction for one fiscal 2028 quarter.

Deutsche Bank AG bought a new stake in Neogen Corporation (NASDAQ:NEOG - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 376,245 shares of the company's stock, valued at approximately $3,382,000. Deutsche Bank AG owned about 0.17% of Neogen at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Dimensional Fund Advisors LP lifted its holdings in shares of Neogen by 23.4% during the first quarter. Dimensional Fund Advisors LP now owns 9,132,021 shares of the company's stock worth $84,831,000 after purchasing an additional 1,733,767 shares during the period. T. Rowe Price Investment Management Inc. increased its stake in Neogen by 249.2% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 8,181,768 shares of the company's stock valued at $57,191,000 after buying an additional 5,838,570 shares during the period. Mackenzie Financial Corp increased its stake in Neogen by 1.0% in the 4th quarter. Mackenzie Financial Corp now owns 7,898,439 shares of the company's stock valued at $55,574,000 after buying an additional 79,010 shares during the period. Cibc World Markets Corp purchased a new position in Neogen during the 4th quarter worth $47,983,000. Finally, Hudson Bay Capital Management LP lifted its stake in shares of Neogen by 30.0% in the 4th quarter. Hudson Bay Capital Management LP now owns 6,500,000 shares of the company's stock worth $45,435,000 after acquiring an additional 1,500,000 shares during the period. Institutional investors and hedge funds own 96.73% of the company's stock.

Key Headlines Impacting Neogen

Here are the key news stories impacting Neogen this week:

• Positive Sentiment: Piper Sandler upgraded Neogen on new management. The brokerage’s improved view suggests investors may expect management changes to improve execution, profitability, or growth. Neogen upgraded at Piper Sandler on new management
• Positive Sentiment: Zacks Research raised several future EPS forecasts. Estimates increased for the second and third quarters of fiscal 2027, the fourth quarter of fiscal 2027, and the third and fourth quarters of fiscal 2028. The full-year fiscal 2028 forecast also rose to $0.29 per share from $0.28, indicating modestly better expected earnings momentum. The current-year consensus remains $0.25 per share.
• Positive Sentiment: Neogen is receiving attention from value-oriented investors. A Zacks comparison of Neogen and Perrigo highlights investor interest in the medical-products sector and could increase visibility for NEOG among investors seeking a relatively attractive valuation. PRGO or NEOG: Which Is the Better Value Stock Right Now?
• Neutral Sentiment: Analysts’ price target is near the recent trading level. The reported consensus target of $11.67 suggests limited near-term upside based on that estimate, although targets can change following the Piper Sandler upgrade. Analysts Set Neogen Corporation PT at $11.67
• Neutral Sentiment: Short-interest data provides no meaningful signal. The report lists zero shares sold short and a zero-day short ratio, figures that appear anomalous and do not indicate either significant short-covering potential or notable bearish positioning.
• Negative Sentiment: Not all forecasts improved. Zacks lowered its fiscal first-quarter 2028 EPS estimate to $0.05 from $0.06, signaling that the earnings outlook remains uneven despite the broader upward revisions.

Neogen Price Performance

Neogen stock opened at $11.70 on Thursday. The company has a market cap of $2.55 billion, a P/E ratio of -390.00, a price-to-earnings-growth ratio of 4.59 and a beta of 1.77. Neogen Corporation has a one year low of $4.90 and a one year high of $12.85. The business has a fifty day moving average of $10.37 and a two-hundred day moving average of $9.85. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.91 and a current ratio of 3.82.

Neogen (NASDAQ:NEOG - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.09 earnings per share for the quarter, topping analysts' consensus estimates of $0.06 by $0.03. The business had revenue of $225.30 million for the quarter, compared to analysts' expectations of $212.35 million. Neogen had a negative net margin of 0.91% and a positive return on equity of 2.78%. The business's revenue for the quarter was down .1% on a year-over-year basis. During the same period in the prior year, the company posted ($2.82) EPS. As a group, analysts predict that Neogen Corporation will post 0.25 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Wall Street Zen raised shares of Neogen from a "hold" rating to a "buy" rating in a report on Saturday, May 9th. Weiss Ratings upgraded shares of Neogen from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, August 7th. Finally, Piper Sandler raised Neogen from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $13.00 to $14.00 in a report on Wednesday. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Neogen presently has a consensus rating of "Hold" and a consensus target price of $12.00.

About Neogen

Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user‐friendly assays to food processors, grain handlers and quality laboratories around the world.

In the food safety arena, Neogen's product lineup includes immunoassay kits, molecular diagnostics and enrichment media for pathogens such as Salmonella, Listeria and E.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source